Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and often
include a dysregulation and dysfunction of the immune system. In the context of population …

Immune checkpoint inhibitors (ICI) have yielded mixed but largely underwhelming results in
clinical trials in patients with acute myeloid leukemia and myelodysplastic syndromes to …

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic
investigation and evaluation of cytopenias of uncertain origin and suspected …

Background Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients
with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years …

Myelodysplastic syndromes (MDS) comprise hematological disorders that originate from the
neoplastic transformation of hematopoietic stem cells (HSCs). However, discrimination …

Ever since hematopoietic cells became “events” enumerated and characterized in
suspension by cell counters or flow cytometers, researchers and engineers have strived to …

Myelodysplastic syndromes (MDS) are hematopoietic malignancies characterized by the
clonal expansion of hematopoietic stem cells, bone marrow failure manifested by …

Motivation Single cell profiling by cytometry has emerged as a key technology in biology,
immunology and clinical-translational medicine. The correct annotation, which refers to the …

In work spanning several decades, extensive studies have focused on the properties of
malignant stem cells that drive the pathogenesis of acute myeloid leukemia (AML). However …

The fast-advancing single cell RNA sequencing (scRNA-seq) technology enables
researchers to study the transcriptome of heterogeneous tissues at a single cell level. The …